Sleep Apnea Market Expected to Witness Robust Growth by 2036, Fueled by Novel Pharmacological Therapies and Rising Disease Awareness | DelveInsight

The Sleep Apnea market is expected to expand substantially across the 7MM during the forecast period (2022-2036), driven by the increasing prevalence of obstructive sleep apnea (OSA), improved diagnosis rates, growing awareness among healthcare providers and patients, and the anticipated launch of several innovative pharmacological therapies. Emerging treatments such as AD109 (Aroxybutynin + Atomoxetine) by Apnimed, Retatrutide and Orforglipron by Eli Lilly and Company, and IHL-42X (Acetazolamide + Dronabinol) by Incannex Healthcare are expected to significantly transform the treatment landscape by providing effective non-device therapeutic options for patients with sleep apnea.

DelveInsight's "Sleep Apnea Market Insight, Epidemiology, and Market Forecast-2036" provides an in-depth analysis of the evolving Sleep Apnea market, delivering comprehensive insights into disease epidemiology, current treatment practices, marketed therapies, emerging pipeline products, competitive landscape, and market forecasts across the seven major markets (7MM). The report evaluates historical and forecasted epidemiological trends, market size, treatment uptake, reimbursement landscape, and unmet clinical needs, enabling pharmaceutical companies, investors, and healthcare stakeholders to identify future growth opportunities and formulate strategic business decisions.

Additionally, the report offers a detailed assessment of the current standard of care, emerging pharmacological innovations, patient journey, market access and reimbursement scenarios, therapy uptake projections, and competitive intelligence across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

To know in detail about the Sleep Apnea market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here:
https://www.delveinsight.com/sample-request/sleep-apnea-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Key Takeaways from the Sleep Apnea Market Report

• The Sleep Apnea market across the 7MM is projected to witness significant growth through 2036, primarily driven by the introduction of innovative pharmacological therapies, increasing diagnosis rates, and expanding treatment uptake among patients with obstructive sleep apnea.
• According to DelveInsight estimates, the total market size of Sleep Apnea in the 7MM was approximately USD 660 million in 2025 and is expected to grow substantially by 2036.
• The United States accounted for nearly 76% of the total Sleep Apnea market in 2025, representing the largest market among the seven major markets.
• In 2025, the total prevalent cases of Sleep Apnea across the 7MM were estimated at approximately 223 million, while diagnosed prevalent cases in the United States reached approximately 15 million.
• Obstructive Sleep Apnea (OSA) represented nearly 92% of diagnosed prevalent cases across the seven major markets, highlighting the significant disease burden and commercial opportunity for targeted therapies.
• A major milestone in the treatment landscape was achieved with the approval of ZEPBOUND/MOUNJARO (tirzepatide) in 2024 as the first approved pharmacological therapy for moderate-to-severe OSA in adults with obesity in both the United States and Europe.
• Key companies advancing the Sleep Apnea pipeline include Apnimed, Eli Lilly and Company, and Incannex Healthcare, with promising late-stage candidates such as AD109, Retatrutide, Orforglipron, and IHL-42X.
• Expected launches of these innovative therapies are anticipated to diversify treatment options beyond traditional CPAP-based management and support long-term market expansion.

Key Factors Driving the Sleep Apnea Market

Rising Disease Awareness and Improved Diagnosis
Growing awareness regarding the long-term health consequences of untreated sleep apnea, coupled with increasing utilization of home sleep apnea testing (HSAT), polysomnography, and standardized screening tools such as STOP-Bang, is enabling earlier diagnosis and expanding the diagnosed patient population across major markets.

Emergence of Innovative Pharmacological Therapies
Historically, sleep apnea management has relied heavily on positive airway pressure devices, oral appliances, lifestyle modifications, and surgical interventions. The emergence of novel oral therapies and obesity-targeted pharmacological treatments is expected to reshape the treatment paradigm by providing less invasive, more convenient therapeutic options that may improve long-term patient adherence.
Increasing Prevalence of Obesity and Associated Comorbidities

The growing prevalence of obesity, cardiovascular disease, diabetes, hypertension, and metabolic disorders continues to contribute significantly to the rising incidence of obstructive sleep apnea worldwide. These underlying risk factors are expected to sustain demand for effective therapeutic interventions throughout the forecast period.

Expanding Clinical Development Activities

Multiple late-stage clinical programs evaluating novel mechanisms of action-including muscarinic receptor antagonists, noradrenaline reuptake inhibitors, GLP-1 receptor agonists, GIP/GLP receptor agonists, and combination therapies-are accelerating innovation within the Sleep Apnea therapeutic landscape and strengthening future market prospects.

Sleep Apnea Market Analysis

Sleep apnea remains one of the most prevalent chronic sleep disorders worldwide, with obstructive sleep apnea accounting for the overwhelming majority of diagnosed cases. Despite the availability of effective device-based therapies such as continuous positive airway pressure (CPAP), long-term treatment adherence remains a major clinical challenge, with many patients discontinuing therapy because of discomfort, inconvenience, or poor compliance. Consequently, there remains substantial unmet need for effective pharmacological treatments capable of improving clinical outcomes while enhancing patient convenience and adherence.

The approval of ZEPBOUND/MOUNJARO (tirzepatide) has marked a significant advancement by introducing the first approved pharmacologic treatment specifically indicated for moderate-to-severe OSA in adults with obesity. Looking ahead, several investigational therapies-including AD109, Retatrutide, Orforglipron, and IHL-42X-have demonstrated encouraging clinical progress and are expected to further transform the competitive landscape through differentiated mechanisms of action and improved efficacy profiles.

Growing physician awareness, broader adoption of home-based diagnostic testing, increasing obesity prevalence, expanding reimbursement support, and continued investment in innovative therapies are expected to drive substantial market growth throughout the forecast period. As pharmacological treatment options continue to evolve, the Sleep Apnea market is anticipated to transition from a predominantly device-dependent treatment model toward a more diversified therapeutic ecosystem focused on personalized and patient-centric care.

Get a Free sample for the Sleep Apnea Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/sample-request/sleep-apnea-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Sleep Apnea Competitive Landscape

The Sleep Apnea therapeutic landscape is undergoing a significant transformation with the emergence of innovative pharmacological therapies designed to complement or potentially reduce dependence on conventional device-based treatments. While Continuous Positive Airway Pressure (CPAP) remains the gold standard for moderate-to-severe obstructive sleep apnea (OSA), poor long-term adherence and patient intolerance continue to create substantial unmet medical needs. This has accelerated investment in novel oral and injectable therapies targeting the underlying mechanisms of airway collapse, obesity, and respiratory regulation.

Leading pharmaceutical and biotechnology companies, including Eli Lilly and Company, Apnimed, and Incannex Healthcare, are advancing late-stage pipeline candidates that have the potential to redefine the future treatment paradigm.

In addition to marketed therapies such as ZEPBOUND/MOUNJARO (tirzepatide), SUNOSI (solriamfetol), and OZAWADE (pitolisant), several investigational therapies are expected to enter the market during the forecast period, creating significant commercial opportunities across the seven major markets.

Emerging Therapies Driving the Sleep Apnea Market

AD109 (Aroxybutynin + Atomoxetine): Apnimed
AD109 is a first-in-class investigational oral combination therapy consisting of aroxybutynin, a novel antimuscarinic agent, and atomoxetine, a selective noradrenaline reuptake inhibitor (NRI). The therapy is designed to improve upper airway muscle tone during sleep, thereby reducing airway obstruction in patients with obstructive sleep apnea. AD109 is currently being evaluated in two pivotal Phase III clinical trials-LunAIRo and SynAIRgy-covering patients with mild, moderate, and severe OSA.

Clinical momentum for AD109 continues to strengthen. In October 2025, Apnimed presented positive Phase III results at the CHEST Annual Meeting 2025, demonstrating significant reductions in the apnea-hypopnea index (AHI) after 26 weeks of treatment, along with consistent improvements in oxygenation endpoints, including oxygen desaturation index (ODI3) and hypoxic burden. Earlier, in July 2025, the company reported positive topline Phase III data further supporting AD109 as a potential first oral therapy for obstructive sleep apnea. The company also announced plans to submit a New Drug Application (NDA) to the US FDA in early 2026.

Retatrutide: Eli Lilly and Company
Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, primarily developed for obesity and metabolic disorders. Given the strong association between obesity and obstructive sleep apnea, substantial weight reduction achieved with Retatrutide may significantly improve sleep apnea severity and associated clinical outcomes.
The therapy is currently being investigated under Eli Lilly's TRIUMPH Phase III development program, which includes studies evaluating efficacy and safety in obese or overweight individuals with and without type 2 diabetes, including patients diagnosed with obstructive sleep apnea. Successful development may further expand pharmacological treatment options beyond traditional airway management strategies.

Orforglipron: Eli Lilly and Company
Orforglipron is an investigational oral GLP-1 receptor agonist currently in Phase III development. The therapy is being evaluated for its ability to improve obstructive sleep apnea through significant weight reduction while offering the convenience of oral administration compared with injectable incretin therapies. Its clinical development focuses on evaluating reductions in apnea-hypopnea index (AHI) and sleep apnea-specific hypoxic burden.

IHL-42X (Acetazolamide + Dronabinol): Incannex Healthcare
IHL-42X combines acetazolamide, a carbonic anhydrase inhibitor, with dronabinol, a receptor 1 (CB1) agonist, to address multiple physiological mechanisms involved in obstructive sleep apnea. The investigational therapy is currently progressing through Phase II/III clinical development.

In May 2025, Incannex Healthcare completed patient dosing in its US Phase II clinical trial and announced preparations for data analysis and an end-of-Phase II meeting with the US FDA. The company also completed patient enrollment in the global RePOSA Phase II/III study, marking important progress toward potential regulatory approval.

Recent Developments in the Sleep Apnea Treatment Landscape

• In December 2024, ZEPBOUND/MOUNJARO (tirzepatide) became the first pharmacological therapy approved in both the United States and Europe for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity, representing a major milestone in Sleep Apnea management.
• In October 2025, Apnimed presented positive Phase III clinical data for AD109 at the CHEST Annual Meeting, demonstrating clinically meaningful reductions in apnea-hypopnea index and improvements in oxygenation outcomes.
• In May 2025, Apnimed announced that the pivotal SynAIRgy Phase III trial successfully achieved its primary endpoint and confirmed plans to submit an NDA to the US FDA in early 2026.
• In May 2025, Incannex Healthcare completed patient dosing in its US Phase II study of IHL-42X and initiated preparations for regulatory interactions following data analysis.
• In April 2025, Incannex Healthcare announced completion of patient enrollment in the global RePOSA Phase II/III clinical trial evaluating IHL-42X for obstructive sleep apnea.

What is Sleep Apnea?

Sleep apnea is a chronic sleep-related breathing disorder characterized by repeated interruptions in breathing during sleep, resulting in intermittent hypoxia, fragmented sleep, and excessive daytime sleepiness. The condition is broadly classified into Obstructive Sleep Apnea (OSA), caused by upper airway collapse during sleep, and Central Sleep Apnea (CSA), which results from impaired respiratory drive originating in the brain. OSA accounts for the overwhelming majority of diagnosed cases worldwide.

Common symptoms include loud snoring, witnessed episodes of breathing cessation, gasping during sleep, morning headaches, excessive daytime sleepiness, fatigue, cognitive impairment, and poor sleep quality. Major risk factors include obesity, increasing age, hypertension, male sex, alcohol consumption, smoking, and craniofacial abnormalities. Diagnosis typically involves validated screening questionnaires such as STOP-Bang, followed by overnight polysomnography or home sleep apnea testing to determine disease severity using the apnea-hypopnea index (AHI).

Sleep Apnea Epidemiology Segmentation

The Sleep Apnea market report provides detailed epidemiological analysis for the study period 2022-2036 across the seven major markets, segmented into:
• Total Prevalent Cases of Sleep Apnea
• Total Diagnosed Prevalent Cases of Sleep Apnea
• Type-specific Cases of Sleep Apnea (OSA, CSA, and Complex Sleep Apnea)
• Severity-specific Cases of Sleep Apnea
• Age-specific Cases of Sleep Apnea
• Gender-specific Cases of Sleep Apnea
• Country-specific Diagnosed Prevalent Cases in the United States
• Diagnosed Prevalent Cases in EU4 and the United Kingdom
• Diagnosed Prevalent Cases in Japan

Download the report to understand which factors are driving Sleep Apnea epidemiology trends:
https://www.delveinsight.com/sample-request/sleep-apnea-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Scope of the Sleep Apnea Market Report

• Study Period: 2022-2036
• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
• Key Companies: Eli Lilly and Company, Apnimed, Incannex Healthcare, Axsome Therapeutics, Bioprojet, and others
• Marketed Therapies: ZEPBOUND/MOUNJARO (tirzepatide), SUNOSI (solriamfetol), OZAWADE (pitolisant), and others
• Emerging Therapies: AD109 (Aroxybutynin + Atomoxetine), Retatrutide, Orforglipron, IHL-42X (Acetazolamide + Dronabinol), and others
• Market Dynamics: Market Drivers, Barriers, Opportunities, and Challenges
• Competitive Intelligence Analysis: SWOT Analysis, Conjoint Analysis, Pricing Trends, Market Entry Strategies, Therapy Uptake Analysis, and Competitive Benchmarking
• Market Access & Reimbursement: Country-specific reimbursement landscape across the United States, EU4 and the UK, and Japan
• Patient Journey, KOL Insights, Analyst Views, Unmet Needs, and Future Market Opportunities

To know more about companies working in the Sleep Apnea treatment market, visit:
https://www.delveinsight.com/sample-request/sleep-apnea-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents

• Sleep Apnea Market Report Introduction
• Executive Summary
• Key Insights
• Sleep Apnea Market Overview at a Glance
• Disease Background and Overview
• Classification of Sleep Apnea
• Signs, Symptoms, Risk Factors, and Pathophysiology
• Diagnosis and Treatment Guidelines
• Epidemiology and Patient Population
• Country-specific Epidemiology (United States, EU4 and the UK, Japan)
• Patient Journey
• Marketed Therapies
• Emerging Therapies
• Sleep Apnea Market Outlook
• Seven Major Market Analysis (2022-2036)
• Market Size by Therapy
• Pricing Trends and Analogue Analysis
• Therapy Uptake Assessment
• Conjoint Analysis
• Key Market Forecast Assumptions
• KOL Views
• SWOT Analysis
• Unmet Needs
• Market Access and Reimbursement
• Appendix
• Report Methodology
• DelveInsight Capabilities
• Disclaimer

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.